Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 7/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4616899 | 1.00 | CYP3A4 (0.48) | CYP3A4KMT2AALDH1A1KDM4EACE | |
| SCHEMBL5954481 | 1.00 | CYP3A4 (0.48) | CYP3A4KMT2AALDH1A1KDM4EACE | |
| SCHEMBL4399114 | 1.00 | CYP3A4 (0.48) | CYP3A4KMT2AALDH1A1KDM4EACE | |
| Hydrochloric Acid SCHEMBL5549564 | 0.99 | ACE (0.49) | CYP3A4KMT2AALDH1A1KDM4EACE | |
| Hydrochloric Acid SCHEMBL4614963 | 0.99 | ACE (0.49) | CYP3A4KMT2AALDH1A1KDM4EACE | |
| Hydrochloric Acid SCHEMBL5593751 | 0.99 | ACE (0.49) | CYP3A4KMT2AALDH1A1KDM4EACE | |
| Hydrochloric Acid SCHEMBL5791761 | 0.99 | ACE (0.49) | CYP3A4KMT2AALDH1A1KDM4EACE | |
| Hydrochloric Acid SCHEMBL4616123 | 0.99 | ACE (0.49) | CYP3A4KMT2AALDH1A1KDM4EACE | |
| Hydrochloric Acid SCHEMBL5793334 | 0.99 | ACE (0.49) | CYP3A4KMT2AALDH1A1KDM4EACE | |
| SCHEMBL646159 | 0.97 | CYP3A4 (0.48) | CYP3A4KMT2AALDH1A1KDM4EACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118724781-A | Novel chiral amino amide-selenoether ligand and preparation method thereof | 延安大学 | 2024-10-01 | — | — | CN | disclosed |
| EP-1675827-B1 | NOVEL METHOD FOR PREPARATION OF CRYSTALLINE PERINDOPRIL ERBUMINE | SERVIER LAB (FR) | 2009-12-16 | — | — | EP | disclosed |
| US-7456296-B2 | Method for preparation of crystalline perindopril erbumine | LUPIN LTD (IN) | 2008-11-25 | — | — | US | disclosed |
| EP-1864973-A1 | Process for the preparation of perindopril and salts thereof | Sochinaz SA (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007085933-A2 | PROCESS FOR THE PREPARATION OF N-[1-(S)-ETHOXYCARBONYL-1-BUTYL]-(S)-ALANINE-DMT COMPLEX AND ITS USE IN THE PREPARATION OF PERINDOPRIL | GLENMARK PHARMACEUTICALS LIMITED (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070149604-A1 | Reacting perindopril in a solvent selected from N,N-dimethylformamide, dimethoxymethane, 2,2-dimethoxypropane and 1,2-dimethoxyethane with tert-butylamine, crystallization; stereospecific | LUPIN LTD. (IN) | 2007-06-28 | — | — | US | disclosed |
| US-20070032661-A1 | Process for the preparation of intermediates of perindopril | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2007-02-08 | — | — | US | disclosed |
| EP-1675827-A1 | NOVEL METHOD FOR PREPARATION OF CRYSTALLINE PERINDOPRIL ERBUMINE | Lupin Limited (IN) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005037788-A1 | NOVEL METHOD FOR PREPARATION OF CRYSTALLINE PERINDOPRIL ERBUMINE | LUPIN LTD. (IN) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005010028-A1 | ALPHA-AMINO ACID BENZOTHIAZOLYLTHIO ESTER AS INTERMEDIATES FOR MANUFACTURE OF ACE INHIBITORS AND PROCESS FOR PREPARATION THEREOF | LUPIN LIMITED (IN) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032661-A1 | Process for the preparation of intermediates of perindopril | ADH1C, ADH1A, ADH5 | CYP3A4 45/4885KMT2A 1334/4885ALDH1A1 33/4885 |
| US-20070149604-A1 | Reacting perindopril in a solvent selected from N,N-dimethylformamide, dimethoxymethane, 2,2-dimethoxypropane and 1,2-dimethoxyethane with tert-butylamine, crystallization; stereospecific | REN, AGTR2, AGTR1 | CYP3A4 139/4885KMT2A 960/4885ALDH1A1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.